One-year results from the CLASP IID trial and registry showed outstanding results in patients with significant symptomatic degenerative mitral regurgitation (DMR) for Pascal, Edwards Lifesciences Corp ...
SAN FRANCISCO, Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two ...
SAN FRANCISCO, CA—For patients with symptomatic degenerative mitral regurgitation (DMR) and a prohibitive surgical risk, transcatheter edge-to-edge repair (TEER) with either of two approved devices ...
MarketBeat on MSN
Edwards Lifesciences Q2 earnings call highlights
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH Edwards Lifesciences (NYSE:EW) reported ...
Edwards Lifesciences gains attention after fresh valve data as structural heart devices, valuation debate, and healthcare sentiment remain in focus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results